Results 141 to 150 of about 3,274,672 (298)
Cancer Trends: Cancer of the liver and biliary tract
, 2010 Liver cancer consists of two main types—hepatocellular carcinoma (HCC) which accounts for about 60% of cases, and intrahepatic bile duct cholangiocarcinoma (ICC), which accounts for about 20%. The liver is one of the less common cancer sites, about 0.
National Cancer Registry Ireland (NCRI)
core
Perspective: Minneapolis Bloch Cancer Survivor Park [PDF]
, 2003 Although I lack the financial resources to fund a hundred parks across America, I, like Richard Bloch, am a cancer survivor. I am a member (Lymphoma, Class of 1999) of a large and growing club that Bloch has undertaken to represent in his ambitious and ...
Hohmann, Heidi
core
Molecular Oncology, EarlyView.Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach +9 more
wiley +1 more source
Molecular Oncology, EarlyView.LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang +9 more
wiley +1 more source
Cancer survivors and cancer pain
BJA EducationCraig, T., Napolitano, A., Brown, M.
openaire +2 more sources
CEACAM1 participation in breast cancer progression
Molecular Oncology, EarlyView.In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin +3 more
wiley +1 more source
Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer
Molecular Oncology, EarlyView.Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas +16 more
wiley +1 more source
Canadian family physician Medecin de famille canadien, 2013 Patients who have completed therapy for malignant disease face many problems, including the possibility and persistent fear of recurrent disease or a new malignancy. The side effects of therapy, including surgical scars, radiation effects or damage to physiological function may strongly influence patients' complete recovery.
openaire +1 more source
PANoptosis in the pathogenesis of myelodysplastic syndromes
Molecular Oncology, EarlyView.PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla +4 more
wiley +1 more source